Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
Conditions
Asthma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Bensch Clinical Research LLC, Stockton, California, United States
AllerVie Clinical Research, Panama City, Florida, United States
AllerVie Clinical Research, Columbus, Georgia, United States
Paul A Shapero MD, Bangor, Maine, United States
AllerVie Clinical Research, Ellicott City, Maryland, United States
AllerVie Clinical Research, Glenn Dale, Maryland, United States
Nebraska Medical Research Institute, Inc., Bellevue, Nebraska, United States
Allergy Partners Clinical Research, Asheville, North Carolina, United States
Toledo Institute of Clinical Research Inc, Toledo, Ohio, United States
Orion Clinical Research, Austin, Texas, United States
Pharmaceutical Research & Consulting, Inc., Dallas, Texas, United States
Western Sky Medical Research, El Paso, Texas, United States
Allergy, Asthma & Sinus Center, S.C., Greenfield, Wisconsin, United States
Study leads
Philip E. Silkoff, MD
Principal Investigator
Precision ClinOps LLC